Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant atezolizumab with or without tiragolumab in resected TMB-high or MSI-high solid tumors
2022-003708-33Phase 2Active
- Sponsor
- Roche
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Nonhematologic neoplasms comparing Atezolizumab with Atezolizumab + tiragolumab (2 arms). Primary endpoint: Disease-free survival rate. Started Dec 2022; status: active.
02
Drugs
atezolizumabtiragolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-003708-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003708-33.